» Articles » PMID: 34567270

Primary Care and Referring Physician Perspectives on Non-alcoholic Fatty Liver Disease Management: a Nationwide Survey

Overview
Publisher Sage Publications
Specialty Gastroenterology
Date 2021 Sep 27
PMID 34567270
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The optimal approach to screening and risk stratification for non-alcoholic fatty liver disease is challenging given disease burden and variable progression. The aim of this study was to assess primary care physician and referring physician practice patterns regarding non-alcoholic fatty liver disease.

Methods: An anonymous nationwide survey was administered to primary care physicians, endocrinologists, and cardiologists in a: (1) tertiary academic hospital, (2) community hospital, and (3) the American College of Physicians Insider Panel. Survey domains assessed non-alcoholic fatty liver disease knowledge, recommendations for screening, risk stratification, treatment, and referral patterns.

Results: A total of 440 providers completed the survey (35.2% completion rate;  = 82 academic hospital,  = 21 community hospital,  = 337 American College of Physicians). Half were male (51.7%), 78% from internal medicine, with 5% subspecialists. Providers were knowledgeable regarding prevalence and risk factors for non-alcoholic fatty liver disease. 58% would support screening for non-alcoholic fatty liver disease and used liver enzymes to do so. Only 22.5% used serum biomarkers and 23% used transient elastography for risk stratification. Primary reason for referral was advanced fibrosis/cirrhosis. 80% reported barriers to treating non-alcoholic fatty liver disease. There was no consistent diet recommended.

Conclusion: In this nationwide survey, we demonstrated that while overall disease knowledge was good, there was an important disconnect between current guidelines and real-world clinical practice. There is also significant heterogeneity in practice patterns for first-line therapy of non-alcoholic fatty liver disease and the majority of provider's report barriers to treating non-alcoholic fatty liver disease. These findings highlight the potential role for reevaluating screening and risk stratification recommendations in primary care to better align with needs in that setting.

Citing Articles

A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol.

Fishman J, Alexander T, Kim Y, Kindt I, Mendez P J Comp Eff Res. 2024; 13(10):e240085.

PMID: 39301878 PMC: 11426282. DOI: 10.57264/cer-2024-0085.


Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care.

Xiao T, Witek L, Bundy R, Moses A, Obermiller C, Schreiner A J Gen Intern Med. 2024; 40(3):629-636.

PMID: 39060786 PMC: 11861828. DOI: 10.1007/s11606-024-08955-9.


Adherence to a Traditional Mexican Diet Is Associated with Lower Hepatic Steatosis in US-Born Hispanics of Mexican Descent with Overweight or Obesity.

Lopez-Pentecost M, Tamez M, Mattei J, Jacobs E, Thomson C, Garcia D Nutrients. 2023; 15(23).

PMID: 38068856 PMC: 10708445. DOI: 10.3390/nu15234997.


Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.

Eskridge W, Cryer D, Schattenberg J, Gastaldelli A, Malhi H, Allen A J Clin Med. 2023; 12(19).

PMID: 37834859 PMC: 10573476. DOI: 10.3390/jcm12196216.


Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.

Moore J, Wheless W, Zhang J, Marsden J, Mauldin P, Moran W Dig Dis Sci. 2023; 68(7):2946-2953.

PMID: 37193930 PMC: 10659111. DOI: 10.1007/s10620-023-07959-5.


References
1.
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S . Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015; 19(5):597-601. PMC: 4566337. DOI: 10.4103/2230-8210.163172. View

2.
Koehler E, Watt K, Charlton M . Fatty liver and liver transplantation. Clin Liver Dis. 2009; 13(4):621-30. DOI: 10.1016/j.cld.2009.07.010. View

3.
Noureddin M, Jones C, Alkhouri N, Vilar Gomez E, Dieterich D, Rinella M . Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020; 159(5):1985-1987.e4. DOI: 10.1053/j.gastro.2020.07.050. View

4.
Corey K, Klebanoff M, Tramontano A, Chung R, Hur C . Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci. 2016; 61(7):2108-17. PMC: 4920690. DOI: 10.1007/s10620-016-4044-2. View

5.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View